In the latest edition of the Life Sciences Voice Top Five Newsletter we delve into the fourth episode of the leading minds podcast with medtech industry expert Amar Sawhney, we also take a look at Eli Lilly’s obesity drug showing promise, GSK’s HIV drug making it to the European market, and other top news!
In our latest podcast, we had the privilege of hearing from Amar Sawhney, a prominent figure in the healthcare industry and co-founder of successful biotech companies. Sawhney shares his profound insights on achieving unprecedented growth and success by establishing a solid foundation rooted in meaningful science, strong values, and a clear purpose. He highlights the power of blending cutting-edge scientific innovation with ethical principles and a deeper sense of purpose to drive exceptional achievements in the healthcare sector. Aspiring entrepreneurs and industry leaders seeking to make a positive impact in life sciences will find his guidance invaluable.
Exciting news in the fight against obesity! Eli Lilly’s investigational drug, tirzepatide, has shown promising outcomes in two late-stage clinical trials. Among participants with type 2 diabetes and obesity, the drug led to significant reductions in body weight and blood sugar levels. These encouraging results offer hope for those struggling with obesity-related conditions, potentially introducing a much-needed effective treatment option to address this global health concern.
A major breakthrough in HIV prevention is on the horizon! GlaxoSmithKline’s long-acting injectable drug, cabotegravir, has received a recommendation for approval from the European Medicines Agency (EMA). The recommendation follows successful clinical trials involving at-risk populations. If approved, cabotegravir will be a vital addition to existing HIV prevention strategies, providing a convenient and discreet option for individuals seeking protection against HIV infection.
In a significant development for eye health, the FDA has granted approval for Tarsus Pharmaceuticals’ Xydemvy, the world’s first treatment for Demodex blepharitis. This chronic inflammatory eye condition affects numerous individuals worldwide, causing discomfort and vision issues. The approval of Xydemvy marks a crucial milestone in addressing this unmet medical need, offering a promising treatment option to alleviate symptoms and enhance patients’ quality of life.
Innovations in diabetes management are making strides! Glucotracks’ continuous glucose monitoring (CGM) implant has successfully passed its first feasibility study. This revolutionary implantable device aims to transform glucose monitoring for individuals with diabetes, providing continuous and real-time data without the need for frequent finger pricking. The positive outcomes from the initial study are a promising step towards advancing this technology, potentially offering patients a more convenient and accurate way to monitor their glucose levels.
Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.